Manuscripts
January 10, 2024
Prognosis and conditional survival among women with newly diagnosed ovarian cancer
Gynecologic Oncology
Szamreta EA et al
October 18, 2023
Natural history and real-world treatment outcomes for non-small cell lung cancer patients with EGFR exon 20 insertion mutation: An IASLC- ASCO CancerLinQ study
JTO Clinical & Research Reports
Behera M et al
September 20, 2023
Real-world pitfalls of analyzing real-world data: A cautionary note and path forward
JCO Clinical Cancer Informatics
Cooper JD et al
August 30, 2023
Prognostic impact of second primary malignancies in multiple myeloma: An ASCO CancerLinQ Discovery analysis of the modern era [CORRESPONDENCE]
American Journal of Hematology
Gibson S et al
July 28, 2023
Multiple myeloma in adolescent and young adults: An ASCO CancerLinQ and SEER analysis
Clinical Lymphoma, Myeloma & Leukemia
Gibson S et al
May 23, 2023
Health data sharing perspectives of patients receiving care in CancerLinQ-participating oncology practices
JCO Oncology Practice
Jagsi R et al
March 26, 2023
Real-world big-data: Strengths and weaknesses of ASCO's CancerLinQ Discovery multiple myeloma dataset
American Journal of Hematology
DeStefano CB et al
February 22, 2023
Evaluation of cost-effectiveness of adjuvant osimertinib in patients with resected EGFR mutation-positive non-small cell lung cancer
PharmacoEconomics - Open
Verhoek A et al
January 10, 2023
Case studies for overcoming challenges in using big data in cancer
Cancer Research
Sweeney SM et al
Abstracts
January 29, 2024
Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC)
ASCO Genitourinary Cancers Symposium 2024
Bolan P et al
December 7, 2023
Disparities in genetic testing patterns and positivity among patients with breast cancer in the CancerLINQ real-world oncology database
San Antonio Breast Cancer Symposium 2023
Kantor O et al
October 27, 2023
Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database
ASCO Quality Care Symposium 2023
Vento J et al
October 27, 2023
Implementing a BRAF biomarker electronic clinical quality measure in CancerLinQ
ASCO Quality Care Symposium 2023
Drumheller C et al
June 2, 2023
A real-world study of US patients with metastatic ovarian, fallopian tube, and peritoneal cancer (mOFPC) using integrated electronic health records (EHR) and claims datasets.
ASCO Annual Meeting 2023
Avinash P B et al
June 2, 2023
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer
ASCO Annual Meeting 2023
Naidoo J et al
June 2, 2023
Electronic health record (EHR) and genomics-based machine learning (ML) to predict therapeutic effectiveness among patients with hormone-receptor positive (HR)+/HER2-advanced breast cancer (aBC)
ASCO Annual Meeting 2023
Hathi D et al
June 2, 2023
Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets
ASCO Annual Meeting 2023
McKelvey B A et al
June 2, 2023
The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I–III resected NSCLC without known EGFR mutations
ASCO Annual Meeting 2023
Gray J E et al
